A Pilot Open-label Study of Aldose Reductase Inhibition with AT-001 (caficrestat) in Patients Hospitalized for COVID-19 Infection: Results from a Registry-based Matched-control Analysis
Juan Gaztañaga(Winthrop-University Hospital), Stuart D. Katz(Andover Eye Associates), Ravichandran Ramasamy(Diabetes Australia), Shoshana Shendelman(Io Therapeutics (United States)), Glenn I. Fishman(New York University), Ann Marie Schmidt(NYU Langone Health), Karthinathan Thangavelu, Riccardo Perfetti(Inserm)
Cited by 1
Related Papers
Glutaminolysis and Transferrin Regulate Ferroptosis
|Molecular Cell|2015|2k
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
|New England Journal of Medicine|2020|1.1k
N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression
|Journal of Biological Chemistry|1999|862
ST-Segment Elevation in Patients with Covid-19 — A Case Series
|New England Journal of Medicine|2020|858